

FUTURE ONCOLOGY

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES

A NEW MEDICINE PUBLICATION

VOLUME 8, NUMBER 1-12 INDEX

FEBRUARY 2008

TABLE OF CONTENTS

STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER			
PANCREATIC CANCER — PART IV			
NOVEL TARGETED THERAPEUTICS			
CHALLENGES IN THE TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)	1730	<i>Tipifarnib</i>	1750
Heterogeneity	1730	Hedgehog Pathway Signaling Inhibitors	1751
Resistance	1731	<i>Cyclopamine</i>	1752
Animal Models	1732	<i>HhAntag</i>	1752
TECHNOLOGIES EMPLOYED IN NOVEL TARGETED THERAPEUTICS IN PDAC	1733	Mammalian Target of Rapamycin (mTOR) Signaling Pathway Modulators	1753
MAJOR MOLECULAR TARGETS/PATHWAYS IMPLICATED IN PDAC	1733	<i>AP23573</i>	1753
Apoptosis Induction/Enhancement	1738	<i>Everolimus</i>	1754
<i>AEG35156/GEM640</i>	1738	<i>Temsirolimus</i>	1754
<i>Imexon</i>	1738	Other Novel Targeted Therapeutics	1754
<i>Lestaurtinib</i>	1738	<i>AGRO100</i>	1755
<i>LY2181308</i>	1739	<i>AP 12009</i>	1755
<i>MPC-6827</i>	1739	<i>ARRY-142886</i>	1755
<i>RP101</i>	1739	<i>ARQ 501</i>	1756
Arachidonic Acid Pathway Inhibitors	1740	<i>BMS-354825</i>	1757
<i>Celecoxib</i>	1740	<i>Bortezomib</i>	1757
<i>LY293111</i>	1741	<i>CC-401</i>	1757
Aurora Kinase Modulators	1741	<i>GTI 2040</i>	1758
<i>MP235</i>	1743	<i>LY900003</i>	1758
<i>R763</i>	1743	<i>PD0325901</i>	1758
<i>VX-680</i>	1743	<i>Perifosine</i>	1758
Epidermal Growth Factor Receptor (EGFr) Inhibitors	1744	<i>RAV12</i>	1759
<i>Cetuximab</i>	1744	<i>SDX-102</i>	1759
<i>EKB-569</i>	1745		
<i>Erlotinib</i>	1745	PANCREATIC CANCER — PART V	
<i>Gefitinib</i>	1746	ANGIOGENESIS	
<i>Matuzumab</i>	1747	INHIBITORS/ANTIMETASTATIC AGENTS AND TARGETED DELIVERY/GENE TRANSFER APPROACHES	
<i>Panitumumab</i>	1747	ANGIOGENESIS INHIBITORS/ANTIMETASTATIC AGENTS	1762
Farnesyl Transferase Inhibitors (FTI)	1748	Endothelial Monocyte-activating Protein II (EMAP-II)	1762
<i>Lonafarnib</i>	1748	Matrix Metalloproteinase Inhibitors	1762
		<i>BAY 12-9566</i>	1763
		<i>Marimastat</i>	1763
		<i>MMI-166</i>	1763
		<i>Ro28-2653</i>	1764
		Vascular Endothelial Growth Factor (VEGF) Inhibitors	1764
		<i>2C3</i>	1765
		<i>Bevacizumab</i>	1765
		<i>CEP-7055</i>	1766
		<i>CX-3543</i>	1766
		<i>E7080</i>	1770
		<i>IMC-1121b</i>	1770
		<i>Sorafenib</i>	1770
		<i>SU6668</i>	1770
		<i>ZD6474</i>	1771
		Urokinase Plasminogen Activator (uPA) System Inhibitors	1771
		<i>WX-UK1</i>	1771
		<i>WX-671</i>	1772
		Other Antiangiogenesis Agents	1772
		<i>CNTO 859</i>	1772
		<i>Proteinase-activated receptor-2 (PAR2) inhibitor 547m</i>	1772
		<i>Thalidomide analogs</i>	1772
		<i>Volociximab</i>	1772
		Other Antimetastatic Agents	1773
		<i>Anti-ephA2 and anti-ephA4 MAb</i>	1773
		<i>AZM475271</i>	1773
		<i>GCS100 and GCS100LE</i>	1775
		<i>Human aspartyl (asparaginyl) β-hydroxylase (HAAH) inhibitors</i>	1775
		<i>MAb K931</i>	1776
		TARGETED DRUG DELIVERY	1776
		Targeted Toxins	1776
		<i>AS1406</i>	1776
		<i>SS1P [SS1(dsFv)-PE38, SS1-PE38]</i>	1776
		<i>TST10088 and TST1000</i>	1777
		Radioimmunoconjugates	1777
		<i>IMMU-107</i>	1777
		<i>Labetuzumab</i>	1777
		<i>XR303</i>	1778
		<i>YM-1001</i>	1778
		Targeted Cytotoxics	1778

<i>AN-238 and AN-162</i>	1778
<i>Glufosfamide</i>	1778
Gene Transfer	1779
<i>Recombinant adenovirus NK4 (Ad-NK4)</i>	1779
<i>Rexin-G</i>	1781
<i>TNFerade</i>	1781
Oncolytic Viruses	1782
<i>CG5757</i>	1782
<i>Reolysin</i>	1783

PANCREATIC CANCER — PART VI

IMMUNOTHERAPY/VACCINES

IMMUNOTHERAPY CHALLENGES IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)	1785
---	------

Defects in the Cellular Immune Response in PDAC	1786
--	------

Animal Models	1790
---------------	------

ACTIVE-SPECIFIC IMMUNOTHERAPY	1791
-------------------------------	------

Autologous Cell Vaccines	1791
--------------------------	------

<i>APC8024</i>	1791
----------------	------

<i>Foxelpox-CEA-TRICOM</i>	1791
----------------------------	------

<i>Human chorionic gonadotropin β (hCGβ) vaccine</i>	1791
--	------

<i>Mutant ras peptide vaccine</i>	1792
-----------------------------------	------

<i>Oncophage</i>	1792
------------------	------

Allogeneic Tumor-cell Vaccines	1793
--------------------------------	------

<i>GVAX</i>	1793
-------------	------

<i>NemodDC</i>	1794
----------------	------

Peptide/Antigen Vaccines	1794
--------------------------	------

<i>Avicine</i>	1794
----------------	------

<i>GV1001</i>	1794
---------------	------

<i>Insegia</i>	1797
----------------	------

<i>Mesothelin-specific vaccine</i>	1798
------------------------------------	------

<i>MUC1 100-mer peptide vaccine</i>	1799
-------------------------------------	------

<i>MUC1/IL-18 DNA vaccine</i>	1799
-------------------------------	------

<i>Panvac-VF</i>	1799
------------------	------

<i>SAI-TGF-α</i>	1800
------------------	------

MONOCLONAL ANTIBODIES (MAB)	1800
-----------------------------	------

Binding Bodies	1800
----------------	------

Other MAb-based Vaccines	1801
--------------------------	------

<i>PankoMab</i>	1801
-----------------	------

<i>HuABL-364 (IGN311)</i>	1801
---------------------------	------

<i>IGN-1</i>	1801
--------------	------

IMMUNOMODULATION/ IMMUNOSTIMULATION	1802
--	------

Cytokines	1802
-----------	------

<i>Interleukin-12 (IL-12)</i>	1802
-------------------------------	------

<i>Interferon α (IFN-α)</i>	1803
-----------------------------	------

<i>OncoVEX GM-CSF</i>	1803
-----------------------	------

Other Immunomodulators	1803
------------------------	------

<i>Reximmune</i>	1803
------------------	------

<i>Virulizin</i>	1803
------------------	------

MEETING COVERAGE

TARGETING FOR CANCER IMAGING AND THERAPY

FROM THE "IMMUNE, VASCULAR AND
GENE TARGETING FOR CANCER IMAGING
AND THERAPY" MEETING ORGANIZED BY
THE SIDNEY KIMMEL CANCER CENTER,
IN SAN DIEGO, CA.
FEBRUARY 28-MARCH 2, 2005

DELIVERY OF DRUGS TO TUMORS	1806
-----------------------------	------

Enhancing Delivery of Drugs to Tumors	1806
--	------

<i>Stem cells</i>	1806
-------------------	------

<i>Multivalent monoclonal antibodies (MAb)</i>	1806
--	------

<i>Polymerized vesicles (PV)</i>	1806
----------------------------------	------

<i>Pulsed high intensity focused ultrasound (HIFU)</i>	1806
--	------

<i>TC1 MAb</i>	1806
----------------	------

<i>Adoptive cell transfer (ACT)</i>	1807
-------------------------------------	------

Gene Transfer	1807
---------------	------

<i>Lentiviral vectors</i>	1807
---------------------------	------

THERAPEUTIC APPROACHES IN DEVELOPMENT	1808
--	------

Apoptosis Enhancing Approaches	1808
--------------------------------	------

<i>Bcl-2</i>	1808
--------------	------

Oncogene Inactivation	1808
<i>PSF protein and mouse VL30 (mVL30) retrotransposon RNA complexes</i>	1808

<i>Oligonucleotides against jun kinase (JNK)</i>	1809
--	------

<i>MDX-010</i>	1809
----------------	------

Angiogenesis Inhibitors/ Antimetastatic Agents	1809
---	------

<i>Avastin</i>	1809
----------------	------

<i>SKI-606</i>	1809
----------------	------

Oncolytic Measles Virus	1810
-------------------------	------

TECHNOLOGY ADVANCES	1810
---------------------	------

Proteomics	1810
------------	------

<i>FLEXGene (Full Length EXpression-ready) repository</i>	1810
---	------

Target Identification in Prostate Cancer	1811
---	------

DIAGNOSIS, PROGNOSIS AND DISEASE MONITORING	1811
--	------

Molecular Portraits by Cancer Type	1811
---------------------------------------	------

Serum-based Approaches	1811
------------------------	------

Tumor Hypoxia	1812
---------------	------

Stem Cells	1812
------------	------

MALDI (Matrix Assisted Laser Desorption Ionization) Mass Spectrometry	1812
---	------

PHASE I MONOTHERAPY CLINICAL TRIALS IN ONCOLOGY

FROM THE 2005 MEETINGS OF THE
AMERICAN ASSOCIATION OF CANCER
RESEARCH (AACR) AND THE AMERICAN
ASSOCIATION OF CLINICAL ONCOLOGY
(ASCO)

PHASE I MONOTHERAPY CLINICAL TRIALS	1830
--	------

Patient Selection	1830
-------------------	------

Trial Initiation	1830
------------------	------

Dosing and Treatment Schedules	1831
--------------------------------	------

<i>Microdosing/phase 0 clinical trials</i>	1831
--	------

<i>Personalized dosing</i>	1831
----------------------------	------

Informed Consent and Patient Recruitment	1832
---	------

Phase I Clinical Trial Reporting	1833
----------------------------------	------

Decision to Advance Development of Agents Based on Phase I Clinical Trials	1834
--	------

Benefits of Phase I Monotherapy in Oncology	1834
--	------

NOVEL ANTICANCER AGENTS/FORMULATIONS IN PHASE I MONOTHERAPY TRIALS	1835
---	------

Cytotoxic Agents, Targeted Cytotoxics, Apoptosis Inducers, and Immunoconjugates	1835
---	------

<i>AQ4N</i>	1835
-------------	------

<i>C-1311</i>	1836
---------------	------

<i>CHR-2797</i>	1836
-----------------	------

<i>CMC-544</i>	1837
----------------	------

<i>CYC682</i>	1838
---------------	------

<i>DOXO-EMCH</i>	1839
------------------	------

<i>DTS-201</i>	1839
----------------	------

<i>FFC11</i>	1840
--------------	------

<i>FFC14A</i>	1840
---------------	------

<i>KOS-1584</i>	1841
-----------------	------

<i>IPdR</i>	1841
-------------	------

<i>MPC-2130</i>	1842
-----------------	------

<i>MPC-6827</i>	1842
-----------------	------

<i>MST-997</i>	1843
----------------	------

<i>SB-743921</i>	1848
------------------	------

<i>SR271425</i>	1848
-----------------	------

<i>XR5944</i>	1849
---------------	------

Hormone Modulators	1849
--------------------	------

<i>CC-8490</i>	1849
----------------	------

Histone Deacetylase Inhibitors (HDAC)	1850	<i>AG-024322</i>	1874	<i>PRO1762</i>	1914
<i>CRA-024781</i>	1850	<i>AT7519</i>	1875	<i>SPC2996</i>	1915
<i>LBH589</i>	1850	<i>RO4584820</i>	1875	IMMUNOTHERAPEUTICS/ VACCINES	1915
<i>MGCD0103</i>	1852	Spindle Poisons	1876	<i>CHIR-12.12</i>	1915
Regulatory/Targeted Agents, Cell-Cycle Modulators, Angiogenesis Inhibitors, and Vascular Targeting Agents (VTA)	1853	<i>BI 2536</i>	1876	<i>SGN-40</i>	1917
<i>AEE788</i>	1853	<i>C242-DM4</i>	1877	<i>TACI-Ig</i>	1918
<i>AS1411</i>	1854	<i>TPI-287</i>	1877		
<i>ATN-224</i>	1854	<i>TTI-237</i>	1878		
<i>AVE8062A</i>	1855	Other Cytotoxics/Apoptosis Inducers	1883		
<i>AZD0530</i>	1855	<i>Azaspirane</i>	1883	MECHANISMS IN MALIGNANCY	
<i>BAY 57-9352</i>	1855	<i>CB3304</i>	1884	THE C-SRC SIGNAL TRANSDUCTION PATHWAY	1813
<i>BMS-599626</i>	1857	<i>ES-285</i>	1885	THE SRC KINASE FAMILY (SKF)	1813
<i>CTCE-9908</i>	1858	<i>PM00104</i>	1886	c-SRC	1814
<i>CX-3543</i>	1858	<i>PT-523</i>	1886	Bone Metabolism	1815
<i>E7820</i>	1858	<i>RHI</i>	1887	Regulation of Angiogenesis	1816
<i>GRN163L</i>	1859	<i>RTA 401(CDDO) and RTA 402 (CDDO-Me)</i>	1888	Promotion of Metastasis	1816
<i>HGS-ETR2</i>	1860	<i>RTA 744 (WP774) and RTA 769</i>	1889	MALIGNANCIES ASSOCIATED WITH c-SRC	1816
<i>KRN951</i>	1861	<i>S23906</i>	1890	Bone Cancer	1816
<i>LErafAON-ETU</i>	1862	<i>S-CKD602</i>	1891	Breast Cancer	1816
<i>ON01910.Na</i>	1862	<i>SJG-136</i>	1891	Chronic Myelogenous Leukemia (CML)	1817
<i>OXi4503</i>	1862	<i>ZIO-101</i>	1893	Colorectal Cancer	1817
<i>RAV12</i>	1863	TARGETED AGENTS (REGULATORY AGENTS)/ CYTOSTATICS/ANGIOGENESIS INHIBITORS	1894	Ovarian Cancer	1817
<i>SNS-595</i>	1864	Angiogenesis Inhibitors	1894	Pancreatic Cancer	1818
<i>SU014813</i>	1865	<i>BIBF 1120</i>	1894	Prostate Cancer	1818
<i>ZK-304709</i>	1865	<i>CHIR258 (CHIR258LC)</i>	1896	AGENTS IN DEVELOPMENT TARGETING THE c-SRC PATHWAY	1818
Immunotherapy/Vaccines	1865	<i>CP-868,596</i>	1898	AP22408, AP23236, and AP23451	1819
<i>GI-4000</i>	1865	<i>ENMD-1198</i>	1899	AP23464	1819
<i>IGN311</i>	1866	<i>OSI-930</i>	1900	AZD0530	1821
<i>Interleukin-21 (IL-21)</i>	1866	<i>XL880</i>	1900	AZM475271 (M475271)	1822
<i>KW-2871</i>	1868	Aurora Kinase Inhibitors	1901	BMS-354825	1822
<i>Phosphostim</i>	1868	<i>AZD1152</i>	1901	GN963	1826
<i>PSMA-based vaccine</i>	1868	<i>MK0457 (VX-680)</i>	1902	SKI-606	1826
<i>RNA-loaded autologous dendritic cell (DC) vaccine</i>	1869	<i>MLN8054</i>	1903	Other Programs	1827
<i>VX-001</i>	1870	Epidermal Growth Factor Receptor (EGFr) Inhibitors	1903		
NOVEL ANTICANCER AGENTS/ FORMULATIONS IN PHASE I MONOTHERAPY CLINICAL TRIALS		<i>ARRY-33454</i>	1903	THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY IN CANCER	
FROM THE 2005 MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, THE NATIONAL CANCER INSTITUTE AND THE EUROPEAN SOCIETY FOR RESEARCH AND TREATMENT OF CANCER (AACR-NCI-EORTC), AND THE AMERICAN SOCIETY OF HEMATOLOGY (ASH)		<i>BIBW 2992</i>	1904	PART I — LIGANDS, RECEPTORS AND DOWNSTREAM EFFECTORS	
CYTOTOXIC AGENTS/TARGETED CYTOTOXICS/ CELL-CYCLE MODULATORS/APOPTOSIS INDUCERS/IMMUNOCONJUGATES	1874	<i>XL647</i>	1905	THE EPIDERMAL GROWTH FAMILY OF RECEPTORS (ERBB)	1922
Cell-cycle Modulators	1874	Heat-shock Protein 90 (Hsp90) Inhibitors	1906	Epidermal Growth Factor (EGF) Receptor (EGFr or ErbB1)	1923
		<i>CNF-1010</i>	1906	ErbB2 (HER2, HER2/neu, c-neu)	1923
		<i>IPI-504</i>	1907	ErbB3 (HER3)	1923
		<i>KOS-1022</i>	1908	ErbB4 (HER4)	1923
		Other Targeted Therapeutics	1910	EGFR/LIGANDS	1923
		<i>AGS-PSCA</i>	1910	Epidermal Growth Factor (EGF)	1924
		<i>AZD6244 (ARRY-142886)</i>	1910		
		<i>GX15-070</i>	1911		
		<i>PD0325901</i>	1913		

Transforming Growth Factor α (TGF α)	1924	ABERRANT RECEPTOR/LIGAND STATUS	1930	<i>Genzyme</i>	1935
Epiregulin	1924	Gene Amplification	1930	<i>Siemens</i>	1935
Heparin-binding EGF-like Growth Factor (HB-EGF)	1924	Autocrine Stimulation	1930	<i>Ventana Medical Systems</i>	1935
Epigen	1924	Mutations	1930	Other Products	1939
Amphiregulin	1926	DIAGNOSIS/PROGNOSIS/THERAGNOSIS/PHARMACOGENOMICS	1930	<i>Abbott Molecular</i>	1939
Betacellulin	1926	Current Clinical Laboratory Detection Methodologies	1931	<i>AdnaGen</i>	1939
Neuregulins	1926	<i>Immunohistochemistry (IHC)</i>	1931	<i>Beckman Coulter</i>	1939
EGFR DOWNSTREAM SIGNALING	1926	<i>Enzyme-linked immunosorbent assay (ELISA)</i>	1931	<i>DxS</i>	1939
Ligand-dependent Activation	1926	<i>Fluorescent in situ hybridization (FISH)</i>	1932	<i>Epigenomics</i>	1940
Ligand-independent Activation	1926	<i>Polymerase chain reaction (PCR)</i>	1932	<i>Genomic Health</i>	1940
Intracellular Signaling Pathways of the EGFR System	1926	<i>High-resolution melting analysis (HRMA)</i>	1932	<i>Idaho Technology</i>	1940
<i>Phospholipase Cγ (PLCγ)</i>	1926	<i>Quantitative mass spectrometry</i>	1932	<i>Invitrogen</i>	1940
<i>Ras/Raf/mitogen-activated protein kinases (MAPK)</i>	1926	<i>RT-PCR for detection of EGFRαIII</i>	1933	<i>Oncotech</i>	1949
<i>Signal transducers and activators of transcription (STAT)</i>	1927	<i>Newer detection methodologies</i>	1933	<i>Orion Genomics</i>	1949
<i>Src</i>	1927	HER2 Testing: IHC versus FISH	1933	<i>Transgenomic</i>	1950
<i>Phosphatidylinositol 3-kinase (PI3K)/Akt</i>	1927	FDA Approved Products	1934	<i>Veridex</i>	1950
<i>Direct and indirect nuclear endpoints of EGFR signaling pathways</i>	1927	<i>Abbott Molecular</i>	1934	Market Opportunities	1950
		<i>Applied Imaging</i>	1934		
		<i>BioGenex</i>	1934		
		<i>Dako</i>	1934		

LIST OF EXHIBITS

TITLE	PAGE	TITLE	PAGE	TITLE	PAGE
Novel Targeted Therapeutics Evaluated Either Clinically or Preclinically for the Treatment of Pancreatic Cancer	1734	Selected Antigens in PDAC Immunotherapeutics	1795	Anticancer Agents in Phase I Monotherapy Clinical Trials with Recently Reported Preclinical or Clinical Findings	1879
Selected Putative Targets of Novel Anticancer Agents in Development for Pancreatic Cancer	1742	Drugs in Development Targeting the Src Pathway	1820	Molecular Targets of Anticancer Agents in Phase I Monotherapy Clinical Trials	1897
Ongoing Randomized Combination Clinical Trials of Cetuximab in PDAC	1749	Phase I Clinical Trial Terminology	1832	EGFR Family Receptors and Major Pathways	1925
Novel Targeted Therapeutics Evaluated Either Clinically or Preclinically for the Treatment of Pancreatic Cancer	1767	Overall Responses in Phase I Clinical Trials	1837	Transmembrane Receptors	1928
Selected Targets of Antiangiogenesis Inhibitors/Antimetastasis Agents and Drug Delivery/Gene Transfer Approaches for Treatment of PDAC	1774	Responses in Monotherapy Phase I Clinical Trials	1841	Structure of the Epidermal Growth Factor Receptor (EGFR)	1932
Ongoing Combination Clinical Trials with Bevacizumab in PDAC	1780	Anticancer Agents in Phase I Monotherapy Clinical Trials with Recently Reported Preclinical or Clinical Findings	1844	Extracellular Ligands of the ErbB Receptor Pathway	1936
Immunotherapies in Clinical or Preclinical Development for the Treatment of Pancreatic Cancer	1787	Responses in Phase I Clinical Trials Involving Regulatory/Antiangiogenesis Agents	1851	Members of Intracellular Pathways Modulated by Activation of ErbB Receptors	1941
		Molecular Targets of Drugs in Phase I Clinical Trials	1856	FDA Approved HER2 and EGFR Tests	1951
		Responses in Phase I Clinical Trials Involving Immunomodulators/Vaccines	1867	Non-FDA Approved and Developmental HER2 and EGFR Tests	1953

INDEX OF COMPANIES & INSTITUTIONS

3M Pharmaceuticals	1797	Array BioPharma	1734, 1742, 1755, 1756, 1879, 1897, 1903, 1910, 1911	Brown University	1746	Christ Church College	1863
Astrom Biosciences	1791	Arthur James Cancer Center	1841	BTG	1835, 1847	Christie Hospital (UK)	1738, 1863, 1888, 1898
Abbott Laboratories	1808, 1934	Asahi Chemical Industry	1768	Burnham Institute	1808, 1880	Chroma Therapeutics	1836, 1844
Abbott Molecular	1934, 1935, 1951, 1952, 1953	Astex Therapeutics	1875, 1879, 1897	Callisto Pharmaceuticals	1879, 1883, 1884	Chugai Pharmaceutical	1787, 1798
Abgenix	1734, 1742, 1747, 1788, 1879, 1880, 1910	AstraZeneca	1734, 1742, 1743, 1746, 1755, 1767, 1771, 1773, 1774, 1775, 1813, 1818, 1820, 1844, 1855, 1879, 1987, 1901, 1904, 1910, 1939, 1940	Cambridge Antibody Technology	1845, 1860	Churchill Hospital (UK)	1835, 1854
Abramson Cancer Center	1750	Attenuon	1844, 1854, 1856	Canadian Genetic Diseases Network	1734, 1738	Ciphergen Biosystems	1737
Academic Medical Center	1777	Auckland Cancer Research Laboratory	1848	Cancer Institute of New Jersey	1762	Cleveland Clinic	1838, 1843
Access Oncology	1758	Augsborg Central Clinic (Germany)	1801	Cancer Research Technology	1844, 1888	Cold Spring Harbor Laboratory	1950
Active Biotech	1787	Australian Cancer Technology	1736, 1739, 1740	Cancer Research UK	1738, 1892	College Medical School (UK)	1863
Aegera Therapeutics	1734, 1738, 1742	Australian Therapeutic Goods Administration (ATGA)	1798	Cancer Therapeutics	1767	Conforma Therapeutics	1880, 1897, 1906
Æterna Zentaris	1734, 1742, 1758, 1767, 1774, 1778	aventis pasteur	1787	Cancer Therapy and Research Center (CTRC)	1758, 1802, 1836, 1877	Cornell University	1787, 1917
Affymetrix	1737, 1940	Aventis	1763	CancerVax	1787, 1800	Cougar Biotechnology	1880, 1884
Agensys	1879, 1897, 1910	Aventis Pharma Deutschland	1839	Case Comprehensive Cancer Center	1832, 1833	Creighton University	1730
Ajinomoto	1847	AVI BioPharma	1736, 1787, 1794, 1856	Case Western University Hospitals of Cleveland	1887	Curis	1735, 1742, 1752, 1753
Alberta Cancer Board	1768	Barbara Ann Karmanos Cancer Institute	1741, 1749, 1768, 1901	Cedars-Sinai Medical Center	1940	Cyclacel	1838, 1847
Alfacell	1734	Baxter Oncology	1769	Celera Genomics Group	1737, 1844, 1850, 1856	Cyclus Pharmaceuticals	1756
AlgoNomics	1788, 1800, 1801	Bay Pines VA Medical Center	1777	Celgene	1772, 1735, 1742, 1757, 1787, 1844, 1849, 1856	Cylene Pharmaceuticals	1766, 1767, 1774, 1845, 1856, 1858
Allos Therapeutics	1879, 1887, 1888, 1897	Bayer Diagnostics	1935, 1951	Center for Molecular Medicine and Immunology (CMMI)	1768, 1777, 1778	CytoGen	1847, 1868
AlphaVax	1869	Bayer	1735, 1767, 1770, 1774, 1844, 1855, 1856	Centocor	1767, 1772, 1774, 1799, 1940	Cytokinetics	1843, 1845
Alza	1879, 1891	Beatson Cancer Center (Scotland)	1825, 1896	Centre Hospitalier		Dainippon Pharmaceutical	1847
American Cancer Society	1813	Beckman Coulter	1939, 1952, 1953	Centre of Molecular Immunology	1769, 1778, 1787, 1800	Dako	1922, 1933, 1934, 1935, 1951, 1952
Amgen	1734, 1747, 1880	Beth Israel Deaconess Medical Center	1746, 1756, 1775, 1887, 1898	Centre René Gauducheau (France)	1868	DakoCytomation	1845
AmpliMed	1734, 1738, 1742	Bioaccelerate Holdings	1841, 1845	Cephalon	1735, 1738, 1742	Dana Farber Cancer Institute (DFCI)	1880, 1883, 1886, 1887, 1898, 1901, 1908, 1917, 1732, 1733, 1735, 1745, 1756, 1788, 1825, 1935
AnorMED	1879	BioFocus	1767, 1781, 1788	Cerus	1787, 1798, 1799	Dartmouth College	1882
Anschutz Cancer Center	1911	Biogen Idec	1733	Charité Berlin	1777	Dartmouth Medical School	1791
AntiGenics	1787, 1792	BioGenex	1934, 1951	Chemokine Therapeutics	1844, 1856, 1858	DC Bio	1844, 1870
Antisense Pharma	1734, 1742, 1755	BioImagene	1934	Children's Hospital Boston	1779, 1787, 1824	Dendreon	1788, 1791
Antisoma	1767, 1774, 1776, 1844, 1854	BioReliance	1768	Chiron	1735, 1767, 1880, 1896, 1897, 1898, 1915	Department of Defense (DoD)	1818
Aphton	1787, 1797, 1798, 1801, 1844, 1856, 1866	BioVex	1767, 1782, 1787, 1803	Chong Kun Dang Pharmaceutical	1879, 1891	Derek Crowther Trials Unit (UK)	1738
Apoptogen	1738	Boehringer Ingelheim	1876			Diatos	1839, 1845
Applied Imaging	1934, 1951	Brigham and Women's Hospital	1731			Duke Comprehensive Cancer Center	1880
Aptamera	1734, 1742, 1755, 1854, 1856	Bristol-Myers Squibb	1735, 1742, 1744, 1757, 1820, 1844, 1856, 1857			Duke University	1791, 1844, 1851, 1866, 1869, 1880, 1887
Archemix	1734, 1755, 1844	Brooke Army Medical Center (BAMC)	1773, 1848			DxS	1939, 1952, 1953
Argos Therapeutics	1844, 1869, 1870					Eisai	1767, 1770, 1774, 1845, 1856, 1858
Ariad Pharmaceuticals	1734, 1742, 1753, 1754, 1819, 1820					Eleos	1735, 1742
Arizona Cancer Center	1738, 1741, 1742, 1743, 1746, 1857, 1862, 1875, 1907					Eli Lilly	1735, 1739, 1741, 1742, 1758, 1788, 1794, 1845
Arizona State University	1846					Emory University	1880, 1884, 1898
ArQule	1756, 1757					EntreMed	1768, 1772, 1774, 1787, 1880, 1899

Enzon Pharmaceuticals 1768, 1774, 1776	Georgetown University 1737, 1800, 1846, 1876, 1878, 1912	Institut Gustav Roussy (France) 1857, 1885	Lineberger Cancer Center 1866, 1870
Epeius Biotechnologies 1767, 1781, 1788, 1803	German Cancer Research Centre 1769	Institute for Drug Development 1852, 1853, 1861	Lombardi Comprehensive Cancer Center 1876, 1878, 1905, 1912
Epigenomics 1940, 1953	Geron 1767, 1783, 1845, 1856, 1859, 1860	Institute of Cancer Research (UK) 1853, 1885	Long Island Jewish Medical Center 1860
Eppley Cancer Center 1876	Glasgow Royal Infirmary (UK) 1898	Invitrogen 1940, 1949, 1954	Lorex Therapeutics 1803
Erasmus Medical Centre (Netherlands) 1885, 1905	GlaxoSmithKline Biologicals 1799	Ipsen 1881, 1891, 1892	Lorus Therapeutics 1736, 1742, 1758
Esteve SA 1769	GlaxoSmithKline 1843, 1845	Ireland Cancer Center 1826, 1887, 1909, 1914	Lurie Comprehensive Cancer Center 1838
European Organization for Research and Treatment of Cancer (EORTC) 1770, 1771, 1772, 1773, 1775, 1779	GlobelImmune 1845, 1856, 1865	Isis Pharmaceuticals 1735, 1739, 1742, 1758, 1809	M. D. Anderson Cancer Center (MDACC) 1741, 1749, 1754, 1757, 1765, 1768, 1770, 1807, 1816, 1818, 1824, 1825, 1826, 1842, 1843, 1853, 1876, 1883
Exelixis 1880, 1897, 1900, 1901, 1905, 1906	GlycoGenesys 1768, 1774, 1775	Istituto Oncologico della Svizzera Italiana (Switzerland) 1855	Makati Medical Center 1781
Faustus Forschungs Compagnie Translational Cancer Research 1840, 1841, 1845, 1856	Grampian Universities NHS Trust (UK) 1849	Ivax 1736	Massachusetts General Hospital 1752, 1756, 1789, 1887, 1935
FDA Oncologic Drugs Advisory Committee 1933, 1934, 1935, 1939, 1951, 1952, 1954	Gray Cancer Institute (UK) 1863, 1895	James Graham Brown Cancer Center 1755, 1854	Massachusetts Institute of Technology (MIT) 1768, 1775
Fletcher International 1787	H. Lee Moffitt Cancer Center and Research Institute 1758, 1898	James P. Wilmot Cancer Center 1876	Maxim Pharmaceuticals 1736, 1739, 1842, 1846
Food and Drug Administration (FDA) 1738, 1755, 1798, 1830, 1831, 1834, 1875, 1893, 1894, 1900, 1908, 1915, 1918, 1933, 1934	Hammersmith Hospital (UK) 1806	Janssen Pharmaceutica 1735, 1742	Mayo Clinic 1810, 1858
Fordham University 1787	Hana Biosciences 1841, 1845, 1880, 1886, 1897	Janssen Research Foundation 1750	McGill University 1870
Fox Chase Cancer Center 1748, 1750, 1770, 1771, 1780, 1838, 1839, 1898, 1905, 1911	Harvard College 1845	Janssen-Cilag 1757	McMaster University 1870
Fraunhofer Institute for Toxicology and Experimental Medicine (Germany) 1736, 1739	Harvard Medical School 1731, 1789, 1798, 1810, 1820	Japan Tobacco 1734	Medarex 1791, 1809, 1845
Fred Hutchinson Cancer Research Center 1811	Harvard University 1880, 1901	Jewish General Hospital 1870	Medical Center (UMC) 1788, 1867
Free University (Netherlands) 1886	Heraklion University General Hospital (Greece) 1870	Johannes Gutenberg University (Germany) 1838, 1851	Medical University of Szegeđ 1777
Fresenius Biotech 1788	Hoag Cancer Center 1777	Johns Hopkins University 1735, 1737, 1751, 1752, 1787, 1793, 1794, 1798, 1862, 1883, 1910, 1916	MedImmune 1768, 1773, 1774
Gdansk University of Technology 1847	Hospital Clinic de Barcelona (Spain) 1838	Johnson & Johnson 1748, 1757, 1891, 1950	Medison Pharma 1787
Gemin X Biotechnologies 1880, 1897, 1911	Hospital St. Louis (France) 1838, 1868	Jonsson Comprehensive Cancer Center 1626, 1748, 1751, 1757, 1883, 1907	Medizinische Fakultät der Charité Berlin 1777
GemVax 1788, 1788, 1794, 1797	Human Genome Sciences 1845, 1856, 1860	Julius-Maximilians University 1786	Medizinische Hochschule Hannover (Germany) 1790
GeneLogic 1737	Human Proteome Organisation (UK) 1811	Keryx Biopharmaceuticals 1734, 1758	Memorial Sloan-Kettering Cancer Center (MSKCC) 1746, 1759, 1792, 1843, 1845, 1847, 1869, 1884, 1909, 1910, 1913, 1914
Genentech 1735, 1736, 1752, 1753, 1765, 1809, 1834, 1880, 1914, 1922, 1930, 1933, 1934	Hybridon 1734, 1738	Kimmel Cancer Center 1862	Merck 1736, 1742, 1743, 1881, 1897, 1902, 1903
Genesis Research and Development 1938	Icos 1769	Kings College (UK) 1807	Merck KGaA 1736, 1742, 1744, 1747, 1764
Genetic Therapy 1767, 1783	Idera Pharmaceuticals 1846	Kirin 1845, 1861	MethylGene 1846, 1852, 1856
Genimatas General Hospital (Greece) 1870	Igeneon 1788, 1801, 1866	Klinik für Tumorbiologie (Germany) 1876	Millennium Pharmaceuticals 1757, 1859, 1881, 1888, 1897, 1903
Genomic Health 1940, 1954	ImClone Systems 1742, 1744, 1770, 1774, 1827, 1834, 1922, 1952	Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen (Germany) 1838	Montigen Pharmaceutical 1736, 1742, 1743
Genta 1808	Immuno-Designed Molecules (IDM) 1788	Kosan Biosciences 1841, 1845	Moores Cancer Center 1809
GenVec 1768, 1781	ImmunoGen 1877, 1881, 1897	KuDOS Pharmaceuticals 1835, 1846	Mount Sinai School of Medicine 1787, 1862
Genzyme 1935, 1951, 1952, 1954, 1955	Immunomedics 1768, 1774, 1777	Kyoto University (Japan) 1754, 1782	Mount Vernon Hospital (UK) 1863, 1895
Genzyme Genetics 1935	Impath 1935	Kyowa Hakko Kogyo 1735, 1738, 1827	Multiple Myeloma Research Consortium (MMRC) 1898
Genzyme Oncology 1788	Imperial Cancer Research Fund (ICRF) 1767	Kyowa Pharmaceuticals 1846, 1868	Myriad Genetics 1736, 1842, 1843, 1846
	Imperial College (UK) 1806	Kyushu University 1779	
	Indiana University Cancer Center 1741	Leicester General Hospital (UK) 1836	
	Infinity Pharmaceuticals 1881, 1897, 1907, 1908	Leicester Royal Infirmary (UK) 1835	
	Innate Pharma 1845, 1868		
	Institut Catala de Oncologia (Spain) 1768, 1885		

Myriad Pharmaceuticals	1739	Panacea Pharmaceuticals	1768, 1774, 1775	Roche	1736, 1756, 1764, 1769, 1774, 1800, 1836, 1841, 1845, 1875, 1882, 1897	Southwest Oncology Group (SWOG)	1750
National Cancer Institute (NCI)	1730, 1737, 1738, 1751, 1765, 1767, 1770, 1772, 1773, 1775, 1776, 1778, 1780, 1781, 1791, 1792, 1800, 1831, 1833, 1834, 1844, 1850, 1869, 1874, 1881, 1886, 1888, 1908, 1909, 1914, 1929	Pancreatic Cancer Action Network	1730	Roche Diagnostics	1940	Spirogen	1881, 1891, 1892
National Cancer Research Center (Spain)	1788, 1800, 1801	Paterson Institute for Cancer Research (UK)	1888	Rocky Mountain Cancer Center	1878	St. Bartholomew's Hospital (UK)	1898
National Institutes of Health (NIH)	1776, 1787, 1806, 1807	Pepscan Systems	1788, 1800, 1801	Roswell Park Cancer Institute	1870, 1882, 1883	St. George's Hospital Medical School	1772
NEMOD Biotherapeutics	1788, 1794, 1801	Peregrine Pharmaceuticals	1765, 1769, 1774	Royal Free and University College Medical School (UK)	1892	St. Joseph's Hospital and Medical Center	1778
NeoPharm	1846, 1856, 1862	Perceptive BioSystems	1787	Royal Free Hampstead NHS Trust (UK)	1901	St. Luke's Cancer Center (UK)	1849
New York University	1843	Pfizer	1736, 1745, 1758, 1770, 1787, 1847, 1856, 1865, 1874, 1880, 1881, 1897, 1898, 1913	Royal Marsden Hospital (UK)	1783, 1885, 1896, 1898, 1904, 1909	St. Petersburg Oncology Center (Russia)	1887
Ninewells Hospital (UK)	1849	Pfizer Global Research and Development	1736, 1742	Royal Marsden NHS Foundation Trust (UK)	1837, 1861	St. Petersburg Pavlov State Medical University (Russia)	1887
Nippon Shinyaku	1736	PharmaMar	1881, 1885, 1886	Ruhr University Bochum (Germany)	1747	St. Vincent's Comprehensive Cancer Center	1883
Norris Comprehensive Cancer Center and Hospital	1885	Pharmexa	1797	Saint Bartholomew's Hospital (UK)	1838	Stanford University School of Medicine	1811, 1845, 1861
Norris Cotton Cancer Center	1898	Presbyterian Hospital Medical Center	1910	Salmedix	1736, 1759	State University of New York	1845
Norsk Hydro	1788	Princess Margaret Hospital (Canada)	1758, 1853, 1870	Sankyo	1838, 1847, 1856	Sugen	1769, 1770, 1774, 1865
North Shore University Hospital	1860	Procyon BioPharma	1789	sanofi-aventis	1757, 1763, 1766, 1767, 1826, 1839, 1847, 1848, 1876	Sunesis Pharmaceuticals	1847, 1864
Northern Institute for Cancer Research (UK)	1861, 1875	Progenics Pharmaceuticals	1847, 1868	Santaris Pharma	1882, 1897, 1915	SuperGen	1787
Northwestern University	1740, 1838	Proligo	1736	Sanofi-Synthelabo	1766	Swiss Agency for Therapeutic Products (Swissmedic)	1798
Norwegian Radium Hospital	1788	Protein Design Labs	1769, 1772, 1774, 1788, 1801, 1844, 1866	Sarantis Pharma	1882, 1897, 1915	Sylvestre Comprehensive Cancer Center	1887, 1918
Novacea	1835, 1836, 1846	Protein Mechanics	1763	Sarah Cannon Cancer Center	1741	Symphony Evolution Systems	1880, 1935, 1939, 1955
Novartis	1754, 1757, 1767, 1783, 1813, 1819, 1834, 1846, 1850, 1853, 1856, 1875, 1874, 1955	Proteomika	1788, 1800, 1801	Sarah Cannon Research Institute	1864	Taiho Pharmaceutical	1769, 1846
Novo Nordisk	1848	Providence Portland Medical Center	1867	Schering-Plough	1737, 1742, 1751, 1755, 1842, 1847, 1856, 1865	Takeda Pharmaceutical	1877, 1881
NS Pharma	1736	PSMA Development	1847, 1856, 1869	Scientific Protein Laboratories	1734	Tapestry Pharmaceuticals	1877, 1878, 1882
Ohio State University	1787, 1841	Pulmonology Research Center (Russia)	1887	Seattle Cancer Care Alliance	1866	Tarcanta	1800
Oncogene Science Group	1935, 1951	Purdue Research Foundation	1768, 1773	Seattle Genetics	1882, 1897, 1917, 1918	Targeted Genetics	1768
Oncolytics Biotech	1768, 1774, 1783	Purdue University Cancer Center	1773	Semmelweis University	1777	Taussig Cancer Center	1838
Onconova Therapeutics	1846, 1856, 1862	Qiagen	1940	Serono	1882, 1897, 1918	Taxolog	1843, 1847
Oncoscience	1769, 1778	Radiation Therapy Oncology Group	1750	Shands Hospital and Clinics	1758	Tayside Cancer Center (UK)	1849
Oncotech	1949, 1952, 1954	Raven Biotechnologies	1736, 1759, 1847, 1856, 1863	Sharp Clinical Oncology Research	1775	Technical University of Munich	1771
Onyx Pharmaceuticals	1735, 1767, 1770	Raylo Chemicals	1844	Sheba Medical Center (Israel)	1878	Temple University	1862
Orion Genomics	1949, 1950, 1954	Reata Pharmaceuticals	1882, 1888, 1889	Shionogi	1763, 1769, 1774	Texas A&M University	1882, 1889, 1893
Ortho Biotech	1735, 1757	Regina Elena National Cancer Institute (Italy)	1740	Sidney Kimmel Comprehensive Cancer Center	1793, 1798, 1799, 1806, 1809, 1812, 1862, 1883, 1910, 1916	Therion Biologies	1789, 1791, 1799, 1800
Osaka Medical College	1782	RESprotect	1736, 1739, 1740, 1742	Siemens	1935, 1951, 1954	Threshold Pharmaceuticals	1769, 1778, 1779
Osaka University Graduate School	1779	Rhode Island Hospital	1768	Sigma-Tau	1787	Tohoku University	
OSI Pharmaceuticals	1736, 1742, 1745, 1812, 1881, 1897, 1900, 1904, 1935	Ricerca Biosciences	1767	Signase	1827	Tohoku University (Japan)	1780, 1790
Ospedale S. Giovanni (Switzerland)	1855	Rigel Pharmaceuticals	1736, 1742, 1743	Sirna Therapeutics	1845	Transgenomic	1845, 1950, 1954
OXiGENE	1862, 1863			Southampton General Hospital (UK)	1888	Translational Genomics Research Institute	1736
				Southern Europe New Drug Organization (SENDO; Italy)	1855	Trion Pharma	1788
						Tripes	1827

Triton BioSystems	1789, 1801, 1802	University of Florida	1758, 1781, 1822	University of Texas Southwestern Medical Center (UTSW)	1737, 1769, 1833, 1845, 1882, 1889, 1893	Westchester Medical Center	1878
Tulane University	1767	University of Freiburg (Germany)	1839, 1857, 1895	University of Texas	1827	Whitehead Institute	1787
Twinstrand Therapeutics	1769, 1774, 1777	University of Heidelberg (Germany)	1746, 1752, 1790	University of the District of Columbia	1737	Wilex	1769, 1771, 1772, 1774, 1776
UCB Pharma	1837, 1846, 1856	University of Helsinki (Finland)	1814	University of Toronto (Canada)	1870	Wyeth	1737, 1742, 1745, 1754, 1820, 1826, 1837, 1838, 1843, 1847, 1878, 1882
UCLA School of Medicine	1781	University of Kiel (Germany)	1744	University of Vienna (Austria)	1841	Xanthus Life Sciences	1831, 1832, 1836, 1847
Ullevål Hospital	1797	University of London (UK)	1846	University of Virginia	1844	Xceleron	1831
United Therapeutics	1789	University of Louisville	1755, 1854	University of Washington	1867	Xenova Group	1769, 1774, 1778, 1848, 1849
Universitaetsklinikum Bonn (Germany)	1838, 1841	University of Mainz (Germany)	1851	University of Wisconsin	1843	Xoma	1789, 1801, 1802, 1880
Universitaetsklinikum Leipzig	1777	University of Manchester (UK)	1835	University of Wisconsin Comprehensive Cancer Center	1773	Yale University	1749, 1764, 1808, 1845
Universitaire Vaudois (Switzerland)	1838	University of Manitoba (Canada)	1736	University of Wisconsin	1731	YM Biosciences	1769, 1774, 1778
University Hospital Gasthuisberg (Belgium)	1853	University of Massachusetts	1735, 1757	University of California Los Angeles (UCLA)	1824, 1825	Ziopharm Oncology	1882, 1893
University Hospital Malmö (Sweden)	1730	University of Miami	1817, 1917, 1918	US Oncology	1781	Zymed	1940, 1949
University Hospital of Erlangen (Germany)	1870	University of Michigan	1844, 1867	Vall d'Hebron University Hospital (Spain)	1747, 1853, 1857	ZymoGenetics	1848, 1866, 1882, 1918
University Hospital of Schleswig-Holstein (Germany)	1747	University of Munich-Großhadern LMU (Germany)	1775, 1822	Vanderbilt University	1883		
University Louis Pasteur (France)	1788, 1801	University of Navarre (Spain)	1802	Vanderbilt University Medical Center	1812		
University Medical Center (UMC; Netherlands)	1800	University of Nebraska Medical Center	1876	Vanderbilt-Ingram Cancer Center	1843, 1848, 1893		
University of Alabama	1745, 1802, 1868	University of Nevada School of Medicine	1889	Varian Medical Systems	1768		
University of Arizona	1736, 1738, 1741, 1743, 1767, 1845, 1858	University of Newcastle upon Tyne (UK)	1875	Vaxon Biotech	1847, 1870		
University of Bologna (Italy)	1826	University of North Carolina-Chapel Hill (UNC-CH)	1866	Ventana Medical Systems	1935, 1939, 1955		
University of Bradford (UK)	1835	University of Nottingham (UK)	1787	Veridex	1950, 1955		
University of Calgary	1768	University of Pennsylvania	1732	Vertex Pharmaceuticals	1736, 1743, 1881, 1901, 1902, 1903		
University of California Irvine	1782, 1870	University of Pittsburgh	1777, 1799, 1832, 1833, 1843, 1880, 1891, 1909	ViRexx Medical	1789		
University of California Los Angeles (UCLA)	1857, 1879, 1883, 1907	University of Regensburg (Germany)	1764	Virginia Commonwealth University	1781		
University of California San Diego (UCSD)	1736, 1757, 1759, 1769, 1790, 1809, 1912, 1922	University of Rochester	1775, 1876	Virginia Mason Medical Center	1777		
University of California San Francisco (UCSF)	1732, 1752	University of Salford (UK)	1879, 1888	VU Medical Center (the Netherlands)	1865		
University of California	1735, 1757, 1845	University of South Florida	1781	VU University Medical Center	1769, 1776		
University of Chicago	1744, 1749, 1765, 1770, 1775, 1780, 1782, 1833, 1850, 1853, 1887	University of Southern California (USC)	1809, 1885	Vysis	1933, 1934		
University of Colorado	1770, 1845, 1866, 1876, 1879, 1888, 1910, 1911, 1914	University of Sydney (Australia)	1733	Walter Reed Army Institute of Research (WRAIR)	1788		
University of Dresden (Germany)	1740	University of Texas	1754	Washington Hospital Center	1777		
University of Edinburgh Cancer Research Centre (UK)	1738	University of Texas Health Science Center	1746	Washington University School of Medicine	1789, 1815		
University of Essen Medical School (Germany)	1841			Wayne State University	1768, 1855, 1901		
				Weill Medical College	1917, 1918		
				Weill Presbyterian Hospital	1884		

ORDERING & INQUIRY INFORMATION

FUTURE ONCOLOGY:

FUTURE ONCOLOGY (ISSN 1082-331X) is published as 12 issues (several double issues) per subscription period with a free annual index listing companies/institutions and subjects covered. FUTURE ONCOLOGY is available in hard copy format or as a PDF file sent as an attachment.

- YES, I want to order a subscription to FUTURE ONCOLOGY.

Subscription Information:

- One-year subscription is \$840 PDF, \$1,040 Hard Copy domestic and \$1,100 Hard Copy foreign. Please specify period (from _____ to _____). Additional subscriptions for the same location are \$390 each.

Back Issues:

- Volumes V4, V5, V6 and V7 Hard Copy or PDF are \$2,450.
- Volumes V6 and V7 PDF only are \$1,500.
Specify Hard Copy _____ or PDF _____

Inquiry Information:

- Please send me a sample issue of FUTURE ONCOLOGY

Oncology KnowledgeBASE (nm|OK):

- YES, I want to order a order nm|OK.

nm|OK is available by subscription only and access is provided via a password. The annual subscription rate is \$3,490 for the first 'seat' and \$340.00 for each additional seat in the same physical location. Subscription rates for company-wide distribution are negotiable, based on physical location/IP designation and number of users. Please enter my subscription to nm|OK to start on (date) _____ at \$3,490.00 _____
Additional seats # _____ at \$340.00 each _____
Total _____

Inquiry Information:

- Please call me for a walk-through the database and a complimentary pass.

All orders must be prepaid or accompanied by a signed order form or P.O. #. Subscriptions to FUTURE ONCOLOGY and nm|OK will begin upon receipt of payment. Products are nonreturnable, subscriptions may be transferred to others in the company.

My check for \$ _____ is enclosed (make checks payable to NEW MEDICINE, INC.). Payment must accompany your order; checks must be drawn on a U.S. bank

Wire Transfer:

Washington Mutual, 400 East Main Street.
Stockton, CA 95290. 800-374-4646. Routing #321180748.
NEW MEDICINE INC. Account #087900008012618

Credit Card: Visa AmEx M/C Exp. Date: _____

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Bill me on P.O. #: _____

Signature: _____

Name: _____

Title: _____ Company: _____

Address: _____

City: _____ State: _____

Zip Code: _____ Country: _____

Telephone: _____ Fax: _____

E-mail _____

Return to: NEW MEDICINE, INC.:

P.O. Box 909 • Lake Forest • CA 92609
Telephone: (949) 830-0448 • Fax: (949) 830-0887
E-mail: info@newmedinc.com
Web Sites: www: newmedinc.com
www.nmok.net

FUTURE ONCOLOGY Staff:

PUBLISHER AND EDITOR:	Katie Sifaca
VICE PRESIDENT-OPERATIONS:	Beth Schweitzer
CONTRIBUTING EDITOR:	Timothy Tankosic, MD
ASSOCIATE EDITOR:	Sudha Khurana, PhD
DESIGN & PRODUCTION:	Jill Burch

Sale of NEW MEDICINE hard copy and electronic publications is made under the following conditions:

Unauthorized photocopying, distribution or electronic storage is strictly prohibited. Information incorporated in NEW MEDICINE products is developed from various sources believed to be reliable. There can be no assurance that such information is accurate in all respects, however, and the publisher cannot be held liable for errors. Errors, when discovered, will be corrected, Subscriptions may not be canceled, but may be transferred.